Fostamatinib – ITP

Fostamatinib


Oral SYK Inhibitor for ITP:


  • Immune Thrombocytopenic Purpura (ITP) is an autoimmune disease where the immune system attacks and destroys platelets in the blood. The result - abnormally low platelet counts.
  • There are two forms of ITP: acute thrombocytopenic purpura, which is most commonly seen in young children; and chronic thrombocytopenic purpura, which requires continual follow up care with a hematologist.
  • There are approximately 60,000 to 125,000 patients with ITP in the U.S., and it qualifies as an orphan disease.
  • Rigel is focusing its Fostamatinib ITP program on the chronic form of this disorder targeting the underlying autoimmune cause of the disease rather than stimulating platelet production.
  • Antibodies, usually of the IgG type, mediate platelet destruction in ITP. Fostamatinib has a novel mechanism of action, blocking IgG receptor signaling in both macrophages and B cells via SYK kinase.
  • Rigel completed and reported results from the FIT Phase 3 clinical program of fostamatinib in ITP.

NEWS - Fostamatinib Study Results Continue to Trend Positive
PUBLICATION - Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk

MOA Animation: